EcoDrugPlus

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSSARG00000007367
Gene Symbol: MAPK10
1 External references
147 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSSARG00000003065
Gene Symbol: MAPK14
1 External references
276 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSSARG00000013973
Gene Symbol: MAPK8
1 External references
294 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSSARG00000009461
Gene Symbol: MAP3K1
1 External references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSSARG00000011112
Gene Symbol: MAP3K11
1 External references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSSARG00000001007
Gene Symbol: MAP3K12
1 External references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSSARG00000010942
Gene Symbol: MAP3K13
1 External references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSSARG00000009787
Gene Symbol: MAP3K5
1 External references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSSARG00000011161
Gene Symbol: MAP3K8
1 External references
198 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSSARG00000014230
Gene Symbol: MAOA
1 External references
147 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSSARG00000014232
Gene Symbol: MAOB
1 External references
330 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSSARG00000010555
Gene Symbol: MLNR
1 External references
165 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).